Golden
Athersys

Athersys

A biopharmaceutical company developing therapeutic products for the treatment of diseases.

Cleveland biotechnology company Athersys Inc received Fast Track designation from the U.S. Food and Drug Administration in acute respiratory distress syndrome, or ARDS.



In January 2019,the company ran a randomized, double-blind placebo-controlled exploratory Phase 2 clinical study evaluating MultiStem administration to patients with ARDS.



In the study, patients who received MultiStem treatment within several days after being diagnosed with ARDS and being placed on a ventilator experienced lower mortality, increased ventilator-free days, and increased ICU-free days during the initial 28-day clinical assessment period relative to patients receiving placebo.



Athersys' partner in Japan, Healios K.K., enrolled patients in a clinical trial evaluating administration of MultiStem to pneumonia-induced ARDS patients in Japan.

Timeline

People

Name
Role
Related Golden topics

Anthony Ting

Employee



Garrett Van Wagoner

Investor



Jason Zilles

Employee



Jim Kovach

Employee



Marc DePaul

Employee



Norbert Varga

Employee



Further reading

Title
Author
Link
Type
Date

Athersys Enters Into New $100 Million Equity Facility with Aspire Capital

Athersys, Inc.

Web



Athersys Inc. extends agreement with Healios for a license to MultiStem therapy for indications in China

Scott Suttell

Web



Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent

Seekingalpha

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References